Italia markets closed

Dow Jones
39.815,70
-187,89(-0,47%)
Nasdaq
16.797,64
+111,68(+0,67%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0865
-0,0007(-0,07%)
Bitcoin EUR
64.005,39
+3.039,52(+4,99%)
CMC Crypto 200
1.451,19
+96,78(+7,15%)

NVCR Jan 2026 12.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,4200

-0,8800

(-26,67%)

In data: 03:22PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in